Literature DB >> 8311772

Anterior segment complications after helium ion radiation therapy for uveal melanoma. Radiation cataract.

W J Meecham1, D H Char, S Kroll, J R Castro, E A Blakely.   

Abstract

OBJECTIVE: To delineate the factors in the development of visually significant cataract after helium ion irradiation of eyes with uveal melanomas.
DESIGN: Retrospective analysis with multivariate analysis using life tables and Cox proportional hazard models in addition to other nonparametric techniques. PATIENTS: All patients with a noncataractous other eye and adequate dosimetry data who were treated with helium ion irradiation.
RESULTS: Significant cataracts (grade 3+ or 4+ on a 0 to 4+ scale) developed in 129 patients (44%). The risk of cataract development peaked at 3 years (25% per person-year) and then declined to a sustained level of 7% to 9% per year after 7 years. In multivariate analysis, the percentage of lens included in the treatment port was the predominant predictive correlate with time to significant cataract (relative risk of 2.97 for a 25% increase in the percentage of lens in the treatment port). Patient age, preexisting cortical opacity, and ultrasound tumor height were also significant; ciliary body involvement and tumor dose had smaller effects. Kaplan-Meier analysis demonstrated an increased rate of cataractogenesis with each increment of the percentage of lens in the treatment port; when more than half of the lens was in the beam, the risk of cataract exceeded 90% within 7 years.
CONCLUSIONS: Cataract development after helium ion irradiation is a function of the amount of the lens in the beam. Unlike neovascular glaucoma that develops mainly in the first few years after treatment, cataract continues to develop during the entire length of follow-up.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8311772     DOI: 10.1001/archopht.1994.01090140073026

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  9 in total

1.  A randomized, controlled trial of varying radiation doses in the treatment of choroidal melanoma.

Authors:  E S Gragoudas
Journal:  Trans Am Ophthalmol Soc       Date:  1998

2.  Concurrent versus sequential application of ferromagnetic hyperthermia and 125I brachytherapy of melanoma in an animal model.

Authors:  W F Mieler
Journal:  Trans Am Ophthalmol Soc       Date:  1997

3.  Long-term follow-up after uveal melanoma charged particle therapy.

Authors:  D H Char; S M Kroll; J Castro
Journal:  Trans Am Ophthalmol Soc       Date:  1997

4.  Development and validation of a patient based measure of outcome in ocular melanoma.

Authors:  A J Foss; D L Lamping; S Schroter; J Hungerford
Journal:  Br J Ophthalmol       Date:  2000-04       Impact factor: 4.638

5.  Predictive factors for the development of rubeosis following proton beam radiotherapy for uveal melanoma.

Authors:  A J Foss; I Whelehan; J L Hungerford; D F Anderson; R D Errington; A Kacperek; M Restori; J Kongerud; M Sheen
Journal:  Br J Ophthalmol       Date:  1997-09       Impact factor: 4.638

6.  Radiation related complications after ruthenium plaque radiotherapy of uveal melanoma.

Authors:  P Summanen; I Immonen; T Kivelä; P Tommila; J Heikkonen; A Tarkkanen
Journal:  Br J Ophthalmol       Date:  1996-08       Impact factor: 4.638

7.  Lauriston S. Taylor Lecture on radiation protection and measurements: what makes particle radiation so effective?

Authors:  Eleanor A Blakely
Journal:  Health Phys       Date:  2012-11       Impact factor: 1.316

8.  Long term visual outcome of radiated uveal melanomas in eyes eligible for randomisation to enucleation versus brachytherapy.

Authors:  D H Char; S Kroll; J M Quivey; J Castro
Journal:  Br J Ophthalmol       Date:  1996-02       Impact factor: 4.638

9.  Metastasis rates and sites after treatment for choroidal melanoma by proton beam irradiation or by enucleation.

Authors:  Chryssanthi Koutsandrea; Marilita M Moschos; Michael Dimissianos; Gerasimos Georgopoulos; Ioannnis Ladas; Michael Apostolopoulos
Journal:  Clin Ophthalmol       Date:  2008-12
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.